Company news

Illumina, Inc. news in 2024

Illumina, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Illumina announces expansion of TruSight Oncology portfolio

November 18, 2024

Illumina To Webcast Upcoming Investor Conferences

November 5, 2024

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2024

November 3, 2024

Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting

October 30, 2024

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers

October 8, 2024

Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024

October 6, 2024

Charles Dadswell to step down as General Counsel, Illumina initiates search for successor

October 2, 2024

European Court of Justice rules in favor of Illumina in jurisdictional appeal

September 2, 2024

FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies

August 26, 2024

Illumina announces strategy to accelerate value creation

August 12, 2024

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024

August 5, 2024

Illumina launches new oncology menu for NovaSeq X Series customers

August 4, 2024

Illumina to Present Upcoming Strategy Update

July 17, 2024

Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

July 10, 2024

Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base

July 8, 2024

Illumina completes the divestiture of GRAIL

June 23, 2024

Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations

June 10, 2024

Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

June 3, 2024

Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares

June 2, 2024

Illumina appoints Everett Cunningham Chief Commercial Officer

June 2, 2024

Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

May 28, 2024

Illumina releases 2023 Corporate Social Responsibility Report

May 27, 2024

Anna Richo joins Illumina's Board of Directors

May 19, 2024

Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL

May 5, 2024

Illumina Reports Financial Results for First Quarter of Fiscal Year 2024

May 1, 2024

Illumina's planned divestment of GRAIL approved by the European Commission

April 11, 2024

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

April 8, 2024

Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024

April 3, 2024

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023

February 7, 2024

Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world

January 14, 2024

Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023

January 8, 2024

Illumina expands collaboration with Janssen to advance molecular residual disease cancer test

January 4, 2024

The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk

January 3, 2024

Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024

January 3, 2024

Calls in 2024

Decks in 2024